
ANRO Stock Forecast & Price Target
ANRO Analyst Ratings
Bulls say
Alto Neuroscience is a clinical-stage biopharmaceutical company with a diverse portfolio of different clinical-stage assets targeting depressive disorders and schizophrenia populations. The company's recent initiation of Phase 2b ALTO-207 study in treatment-resistant depression subjects is a positive sign, as is their focus on maintaining trial quality through eligibility reviews and assessments. Additionally, the company's efficient regulatory pathway, strong management team, and promising early evidence suggest potential for success in the future, making it an interesting investment opportunity.
Bears say
Alto Neuroscience is a clinical-stage biopharmaceutical company with a strong focus on developing personalized treatment options for mental health disorders. However, the company faces a number of fundamental risks, including the potential failure to execute commercially, competition from other biopharmaceutical companies, reliance on third parties for manufacturing and conducting clinical trials, and uncertain protection of its intellectual property. These risks may hinder the company's ability to achieve its target price and potential shareholders should take a cautious approach. Additionally, the company may need to raise additional capital before becoming profitable, which could result in share dilution for existing shareholders.
This aggregate rating is based on analysts' research of Alto Neuroscience Inc and is not a guaranteed prediction by Public.com or investment advice.
ANRO Analyst Forecast & Price Prediction
Start investing in ANRO
Order type
Buy in
Order amount
Est. shares
0 shares